AR070141A1 - Anticuerpos humanizados especificos para el factor von willebrand - Google Patents
Anticuerpos humanizados especificos para el factor von willebrandInfo
- Publication number
- AR070141A1 AR070141A1 ARP090100075A ARP090100075A AR070141A1 AR 070141 A1 AR070141 A1 AR 070141A1 AR P090100075 A ARP090100075 A AR P090100075A AR P090100075 A ARP090100075 A AR P090100075A AR 070141 A1 AR070141 A1 AR 070141A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- von willebrand
- willebrand factor
- vwf
- humanized antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente hace referencia a anticuerpos humanizados o fragmentos de union a los mismos específicos para el factor von Willebrand humano (vWF), a métodos para su preparacion y uso, que incluyen métodos para tratar enfermedades o trastornos mediados por vWF. Fragmentos de anticuerpo, ácidos nucleicos que codifican el anticuerpo o sus fragmentos, un vector, una célula huésped que lo comprende. Reivindicacion 64: Una composicion que comprende un primer anticuerpo humanizado o fragmento de union al mismo de cualquiera de las reivindicaciones 1 a 43 y un segundo anticuerpo que se une al dominio A1 de vWF. Reivindicacion 97: El anticuerpo humanizado o fragmento de union al mismo de la reivindicacion 96, donde el trastorno trombotico es enfermedad cardiovascular o enfermedad cerebrovascular tal como apoplejía isquémica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2302508P | 2008-01-23 | 2008-01-23 | |
US4478708P | 2008-04-14 | 2008-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070141A1 true AR070141A1 (es) | 2010-03-17 |
Family
ID=40613108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100075A AR070141A1 (es) | 2008-01-23 | 2009-01-09 | Anticuerpos humanizados especificos para el factor von willebrand |
Country Status (21)
Country | Link |
---|---|
US (1) | US8236315B2 (es) |
EP (1) | EP2245069B1 (es) |
JP (1) | JP2011510622A (es) |
KR (1) | KR20100113589A (es) |
CN (1) | CN101932606A (es) |
AP (1) | AP2010005332A0 (es) |
AR (1) | AR070141A1 (es) |
AU (1) | AU2009207340A1 (es) |
BR (1) | BRPI0905761A2 (es) |
CA (1) | CA2712221A1 (es) |
CL (1) | CL2009000123A1 (es) |
CO (1) | CO6280500A2 (es) |
DK (1) | DK2245069T3 (es) |
EA (1) | EA201070730A1 (es) |
ES (1) | ES2495092T3 (es) |
IL (1) | IL207134A0 (es) |
MX (1) | MX2010008060A (es) |
PE (1) | PE20091351A1 (es) |
TW (1) | TW200938630A (es) |
WO (1) | WO2009093138A1 (es) |
ZA (1) | ZA201005373B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
HUE035281T2 (en) | 2011-01-14 | 2018-05-02 | Univ California | Therapeutic antibodies to ROR-1 protein and methods of their use |
US20150183885A1 (en) * | 2012-06-08 | 2015-07-02 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗mcam抗體及相關使用方法 |
JP2016527613A (ja) * | 2013-06-26 | 2016-09-08 | モハメッド エラシュワMohammed Elashwah | 医薬品管理における処方、転写および管理誤りを検出するためのシステムおよび方法 |
CN103760358A (zh) * | 2013-11-12 | 2014-04-30 | 赵铁铭 | 一种用于检测冯维勒布兰德因子的试剂及其制备方法和应用 |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
KR20160127825A (ko) | 2014-03-12 | 2016-11-04 | 프로테나 바이오사이언시즈 리미티드 | 항-mcam 항체 및 관련된 사용 방법 |
EP3116906A1 (en) * | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
KR20160131073A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg4-5에 대해 특이적인 항-라미닌4 항체 |
DK3164150T3 (da) * | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
EP3842072A1 (en) | 2015-05-18 | 2021-06-30 | Eureka Therapeutics, Inc. | Anti-ror1 antibodies |
EP3519997A1 (en) * | 2016-09-30 | 2019-08-07 | Novo Nordisk A/S | Systems and methods for communicating a dose history representing an average and a variability of a distribution of medicament injections |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11576840B1 (en) * | 2019-04-26 | 2023-02-14 | INMAR Rx SOLUTIONS, INC. | Medication inventory system including RFID based medication discrepancy determination and related methods |
GB202105625D0 (en) * | 2021-04-20 | 2021-06-02 | Ip2Ipo Innovations Ltd | Von willebrand factor (VWF) inhibitors |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) * | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) * | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) * | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) * | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) * | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) * | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) * | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4927762A (en) * | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
ATE186219T1 (de) | 1993-03-24 | 1999-11-15 | Berlex Biosciences | Kombination von antihormonale und bindende moleküle zur krebsbehandlung |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
KR100406072B1 (ko) * | 1994-11-30 | 2004-03-30 | 아지노모토 가부시키가이샤 | 항혈전제 및 항-폰빌레브란트인자 모노클로날항체 |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
WO1997004801A1 (en) | 1995-07-27 | 1997-02-13 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
CA2344606A1 (en) * | 1998-10-23 | 2000-05-04 | Huabing Yuan | Conformation-specific anti-von willebrand factor antibodies |
HUP0402659A3 (en) * | 2001-05-30 | 2008-07-28 | Glaxo Group Ltd | Chromosome-based platforms |
WO2004006955A1 (en) * | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
EP2322625B8 (en) * | 2001-11-08 | 2016-02-24 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof |
CA2522067C (en) * | 2003-04-09 | 2010-07-06 | Canadian Blood Services | Detection, characterization and treatment of viral infection and methods thereof |
JPWO2005035577A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | ガングリオシドgd3に特異的に結合する抗体組成物 |
AU2004324464A1 (en) * | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
FR2889534B1 (fr) * | 2005-08-04 | 2012-11-02 | Lab Francais Du Fractionnement | Anticorps anti-idiotypique neutralisant l'activite inhibitrice d'un anticorps inhibiteur du facteur viii |
US7744874B2 (en) * | 2007-03-20 | 2010-06-29 | Eli Lilly And Company | Anti-sclerostin antibodies |
-
2009
- 2009-01-09 AR ARP090100075A patent/AR070141A1/es unknown
- 2009-01-21 PE PE2009000068A patent/PE20091351A1/es not_active Application Discontinuation
- 2009-01-22 MX MX2010008060A patent/MX2010008060A/es not_active Application Discontinuation
- 2009-01-22 ES ES09703856.6T patent/ES2495092T3/es active Active
- 2009-01-22 CA CA2712221A patent/CA2712221A1/en not_active Abandoned
- 2009-01-22 JP JP2010543586A patent/JP2011510622A/ja not_active Withdrawn
- 2009-01-22 EP EP09703856.6A patent/EP2245069B1/en not_active Not-in-force
- 2009-01-22 CL CL2009000123A patent/CL2009000123A1/es unknown
- 2009-01-22 EA EA201070730A patent/EA201070730A1/ru unknown
- 2009-01-22 CN CN2009801028919A patent/CN101932606A/zh active Pending
- 2009-01-22 DK DK09703856.6T patent/DK2245069T3/da active
- 2009-01-22 BR BRPI0905761-7A patent/BRPI0905761A2/pt not_active IP Right Cessation
- 2009-01-22 AP AP2010005332A patent/AP2010005332A0/en unknown
- 2009-01-22 AU AU2009207340A patent/AU2009207340A1/en not_active Abandoned
- 2009-01-22 KR KR1020107018544A patent/KR20100113589A/ko not_active Application Discontinuation
- 2009-01-22 WO PCT/IB2009/000124 patent/WO2009093138A1/en active Application Filing
- 2009-01-23 TW TW098102855A patent/TW200938630A/zh unknown
- 2009-01-23 US US12/358,682 patent/US8236315B2/en active Active
-
2010
- 2010-07-21 IL IL207134A patent/IL207134A0/en unknown
- 2010-07-28 ZA ZA2010/05373A patent/ZA201005373B/en unknown
- 2010-08-02 CO CO10093896A patent/CO6280500A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US8236315B2 (en) | 2012-08-07 |
WO2009093138A1 (en) | 2009-07-30 |
CN101932606A (zh) | 2010-12-29 |
CO6280500A2 (es) | 2011-05-20 |
JP2011510622A (ja) | 2011-04-07 |
ES2495092T3 (es) | 2014-09-16 |
US20090232804A1 (en) | 2009-09-17 |
CL2009000123A1 (es) | 2010-02-05 |
KR20100113589A (ko) | 2010-10-21 |
AU2009207340A1 (en) | 2009-07-30 |
EP2245069A1 (en) | 2010-11-03 |
ZA201005373B (en) | 2011-06-29 |
AP2010005332A0 (en) | 2010-08-31 |
IL207134A0 (en) | 2010-12-30 |
DK2245069T3 (da) | 2014-09-01 |
BRPI0905761A2 (pt) | 2015-07-14 |
PE20091351A1 (es) | 2009-09-16 |
EA201070730A1 (ru) | 2011-04-29 |
MX2010008060A (es) | 2010-08-10 |
CA2712221A1 (en) | 2009-07-30 |
TW200938630A (en) | 2009-09-16 |
EP2245069B1 (en) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070141A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
CL2021000717A1 (es) | Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018 | |
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
CO2018004094A2 (es) | Polipéptidos de unión a cd3 | |
BR112018000475A2 (pt) | construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3 | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
EA201890169A1 (ru) | Тау-связывающие антитела | |
BR112015017548A8 (pt) | construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit | |
PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
AR064333A1 (es) | Anticuerpo anti-tslp de diseno | |
CL2011000308A1 (es) | Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune. | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
PE20141787A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
CO6382161A2 (es) | Moleculas biespecificas de union a egfr/igfir | |
AR065420A1 (es) | Anticuerpos anti-il-23 p19 de ingenieria | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |